Clinical Trial Update: Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and pharmacodynamic effects of a single dose of SB-656933-AAA in subjects after ozone exposure, in the context of chronic ob…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• SB-656933-AAA

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED